Please use this identifier to cite or link to this item:
|Title:||Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes|
|Source:||Woo, J., Chiu, G.N.C., Karlsson, G., Wasan, E., Ickenstein, L., Edwards, K., Bally, M.B. (2008-02-12). Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. International Journal of Pharmaceutics 349 (1-2) : 38-46. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijpharm.2007.07.020|
|Abstract:||A conventional, cholesterol-containing liposome formulation of cisplatin has demonstrated insignificant activity in clinical trials, due in part, to insufficient release of encapsulated content following localization within solid tumors. For this reason, the development of a triggered release liposome formulation is desirable. In this report, cisplatin was encapsulated into lysolipid-containing thermosensitive liposomes (LTSL) using a novel technique, which relies on the equilibration of cisplatin across the liposomal membrane at temperatures above the gel-to-liquid crystalline phase transition temperature (TC) of the bulk phospholipid. Mild heating and drug loading into LTSL did not induce morphological changes of the liposomes. In vitro data demonstrated that >95% of encapsulated cisplatin was released from LTSL within 5 min following mild heating at 42 °C, while|
|Source Title:||International Journal of Pharmaceutics|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 15, 2018
WEB OF SCIENCETM
checked on Jan 30, 2018
checked on Feb 19, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.